Compass Therapeutics (NASDAQ:CMPX) Posts Earnings Results, Beats Expectations By $0.03 EPS

Compass Therapeutics (NASDAQ:CMPX) posted its earnings results on Tuesday. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03, Zacks reports.

Compass Therapeutics Trading Down 5.3 %

Shares of Compass Therapeutics stock traded down $0.09 on Thursday, reaching $1.60. 237,812 shares of the stock were exchanged, compared to its average volume of 432,202. The firm has a market capitalization of $220.14 million, a PE ratio of -4.47 and a beta of 0.92. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.34. The business has a fifty day moving average price of $1.75 and a two-hundred day moving average price of $1.42.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. LADENBURG THALM/SH SH raised Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective for the company in a report on Monday, September 16th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a research note on Monday. Finally, Wedbush reaffirmed an “outperform” rating and issued a $8.00 target price on shares of Compass Therapeutics in a report on Wednesday, August 7th.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.